Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther. 2010 Feb; 9(2):257-67.